This high-throughput approach revealed synergy between CDKI-73 and AZD5153 in 305R-Cx (AR-negative, neuroendocrine) organoids and an additive effect of these drugs in 201.1A-Cx (AR-positive, CRPC-adenocarcinoma) organoids (Fig. 6e–g; Supplementary Fig. 7), determined using the SynergyFinder Plus tool [54] (see Materials and Methods). The gene discussed is AR; the disease is adenocarcinoma.